{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:11:52Z","timestamp":1698750712421},"reference-count":41,"publisher":"Akademiai Kiado Zrt.","issue":"30","license":[{"start":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T00:00:00Z","timestamp":1627171200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,7,25]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold> A kr\u00f3nikus myeloid leukaemia ritka, klon\u00e1lis \u0151ssejt\n                    eredet\u0171 betegs\u00e9g. A myeloid sejtsor k\u00f3ros m\u0171k\u00f6d\u00e9s\u00e9t a 9-es \u00e9s 22-es kromosz\u00f3m\u00e1k\n                    reciprok transzlok\u00e1ci\u00f3ja k\u00f6vetkezt\u00e9ben kialakul\u00f3 f\u00fazi\u00f3s g\u00e9n (BCR\/ABL1) \u00e1ltal\n                    k\u00f3dolt patol\u00f3gi\u00e1s (fokozott) aktivit\u00e1s\u00fa tirozin-kin\u00e1z jel\u00e1tviteli feh\u00e9rje\n                    okozza. A tart\u00f3s, gyakran \u00e9lethosszig tart\u00f3 BCR\/ABL1 specifikus\n                    tirozin-kin\u00e1z-g\u00e1tl\u00f3 (TKI-) kezel\u00e9s a betegek jelent\u0151s h\u00e1nyad\u00e1ban az eg\u00e9szs\u00e9ges\n                    popul\u00e1ci\u00f3 t\u00fal\u00e9l\u00e9s\u00e9t el\u00e9r\u0151 teljes gy\u00f3gyul\u00e1st biztos\u00edt, melyhez folyamatos, a\n                    mindenkori szakmai aj\u00e1nl\u00e1soknak megfelel\u0151 onkohematol\u00f3giai ellen\u0151rz\u00e9s sz\u00fcks\u00e9ges.\n                    Az igen hat\u00e9kony TKI-kezel\u00e9s mellett azonban nemk\u00edv\u00e1natos mell\u00e9khat\u00e1sok\n                    jelentkezhetnek, melyek \u2013 sz\u00e1mos szervrendszert \u00e9rintve \u2013 a kr\u00f3nikus myeloid\n                    leukaemi\u00e1s beteg kezel\u00e9s\u00e9t multidiszciplin\u00e1ris egy\u00fcttm\u0171k\u00f6d\u00e9ss\u00e9 sz\u00e9les\u00edtik ki.\n                    Jelenleg Magyarorsz\u00e1gon \u00f6tf\u00e9le TKI \u00e9rhet\u0151 el, melyek mell\u00e9khat\u00e1sprofilja igen\n                    elt\u00e9r\u0151. A kezel\u00e9s elind\u00edt\u00e1sakor, illetve ter\u00e1piam\u00f3dos\u00edt\u00e1s eset\u00e9n beteg- \u00e9s\n                    k\u00f3rk\u00e9pspecifikus szempontokat m\u00e9rlegelve kell kiv\u00e1lasztani az adott\n                    TKI-kezel\u00e9st. Tekintettel a tart\u00f3s kezel\u00e9s mellett el\u00e9rhet\u0151 kiv\u00e1l\u00f3 t\u00fal\u00e9l\u00e9si\n                    eredm\u00e9nyekre, egyre gyakoribb azoknak a kr\u00f3nikus myeloid leukaemi\u00e1s betegeknek a\n                    sz\u00e1ma, akikn\u00e9l v\u00e1ltoz\u00f3 s\u00falyoss\u00e1g\u00fa nemk\u00edv\u00e1natos mell\u00e9khat\u00e1sok jelentkeznek,\n                    melyek miatt a betegek sokszor nem a hematol\u00f3gus szakorvosn\u00e1l jelentkeznek. A\n                    leggyakrabban \u00e9szlelt sz\u00f6v\u0151dm\u00e9nyek ismertet\u00e9s\u00e9t saj\u00e1t beteganyagunk r\u00e9szletes\n                    elemz\u00e9se kapcs\u00e1n a mindennapi klinikai gyakorlatban is bemutatjuk. Igen fontos,\n                    hogy a t\u00e1rsszakm\u00e1k (h\u00e1ziorvos, belgy\u00f3gy\u00e1sz, kardiol\u00f3gus, angiol\u00f3gus,\n                    diabetol\u00f3gus, t\u00fcd\u0151gy\u00f3gy\u00e1sz, gasztroenterol\u00f3gus stb.) gyakorl\u00f3i is tiszt\u00e1ban\n                    legyenek az adott TKI-kezel\u00e9s lehets\u00e9ges mell\u00e9khat\u00e1saival, azok megel\u0151z\u00e9s\u00e9vel,\n                    id\u0151ben t\u00f6rt\u00e9n\u0151 felismer\u00e9s\u00e9vel \u00e9s hat\u00e9kony kezel\u00e9s\u00e9vel. Szakmai k\u00f6zrem\u0171k\u00f6d\u00e9s\u00fck\n                    r\u00e9v\u00e9n \u00edgy seg\u00edthetik a klinikai hematol\u00f3gust a megfelel\u0151 ter\u00e1pia\n                    megtervez\u00e9s\u00e9ben, valamint a betegek folyamatos kezel\u00e9se kapcs\u00e1n gyakran\n                    sz\u00fcks\u00e9gess\u00e9 v\u00e1l\u00f3 szakmaspecifikus gondoz\u00e1s\u00e1ban is. Orv Hetil. 2021; 162(30):\n                    1198\u20131207.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold> Chronic myeloid leukemia is a rare clonal stem cell\n                    disorder. The pathological overproduction of the myeloid cell line is caused by\n                    abnormal function of a tyrosine kinase encoded by a fusion gene (BCR\/ABL1) which\n                    is formed upon a reciprocal translocation of chromosomes 9 and 22. Long-term,\n                    often lifelong treatment with BCR\/ABL1-specific tyrosine kinase inhibitors\n                    provides excellent disease control and overall survival rates close to the\n                    general survival of a healthy population in a significant proportion of\n                    patients. These patients require continuous oncohematological monitoring in\n                    accordance with the current diagnostic and treatment guidelines. However,\n                    undesirable side effects may occur that extend the treatment of the patients to\n                    a multidisciplinary approach involving a number of nonhematological\n                    specialities. Currently, five types of tyrosine kinase inhibitors are available\n                    in Hungary, with very different side effect profiles. At the start of treatment\n                    or in the event of a change in therapy, patient- and leukemia-specific\n                    assessments should be taken to select the most proper tyrosine kinase inhibitors\n                    treatment. Given the excellent survival outcomes achieved with long-term\n                    tyrosine kinase inhibitor treatment, there is an increasing number of patients\n                    who might experience adverse events of different kind or severity, which often\n                    results in patients ending up in different, nonhematological medical situations.\n                    The description of the most frequently observed complications in connection with\n                    a detailed cross-sectional analysis of our own patient cohort is also presented\n                    here resembling everyday clinical practice. It is very important that\n                    practitioners of other medical professions (general practitioner, internist,\n                    cardiologist, angiologist, diabetologist, pulmonologist, gastroenterologist,\n                    etc.) should be aware of the possible side effects of specific tyrosine kinase\n                    inhibitor therapies. They can help to assist the clinical hematologist in\n                    planning the appropriate tyrosine kinase inhibitor therapy as well as in\n                    professional caretaking of these patients. Orv Hetil. 2021; 162(30):\n                    1198\u20131207.<\/jats:p>","DOI":"10.1556\/650.2021.32177","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:03:55Z","timestamp":1630404235000},"page":"1198-1207","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":1,"title":["A kr\u00f3nikus myeloid leukaemia tirozin-kin\u00e1z-g\u00e1tl\u00f3 kezel\u00e9s\u00e9nek mell\u00e9khat\u00e1sai \u00e9s azok gyakorlati ell\u00e1t\u00e1sa"],"prefix":"10.1556","volume":"162","author":[{"given":"Gabriella","family":"Mezei","sequence":"first","affiliation":[{"name":"1 Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati Int\u00e9zet, Hematol\u00f3giai Tansz\u00e9k, Debrecen, Nagyerdei krt. 98., 4032"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[{"name":"1 Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati Int\u00e9zet, Hematol\u00f3giai Tansz\u00e9k, Debrecen, Nagyerdei krt. 98., 4032"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Bat\u00e1r","sequence":"additional","affiliation":[{"name":"1 Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati Int\u00e9zet, Hematol\u00f3giai Tansz\u00e9k, Debrecen, Nagyerdei krt. 98., 4032"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","article-title":"New consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"1 Rowley","year":"1973","unstructured":"1 Rowley JD. New consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.","journal-title":"Nature"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells","volume":"2","author":"2 Druker","year":"1996","unstructured":"2 Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nat Med. 1996; 2: 561-566.","journal-title":"Nat Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"3 Pfirrmann","year":"2016","unstructured":"3 Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016; 30: 48-56.","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia","volume":"34","author":"4 Hochhaus","year":"2020","unstructured":"4 Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia. Leukemia 2020; 34: 966-984.","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"5 Hehlmann","year":"2017","unstructured":"5 Hehlmann R, Lauseker M, Sau\u00dfele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 2017; 31: 2398-2406.","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"6 Kantarjian","year":"2012","unstructured":"6 Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123-1129.","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"7 Hochhaus","year":"2016","unstructured":"7 Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044-1154.","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"8 Br\u00fcmmendorf","year":"2015","unstructured":"8 Br\u00fcmmendorf TH, Cortes JE, de Souza CA, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015; 168: 69-81.","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"9 Druker","year":"2006","unstructured":"9 Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417.","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"10 Cortes","year":"2013","unstructured":"10 Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013; 369: 1783-1796.","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"11 Cortes","year":"2018","unstructured":"11 Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018; 132: 393-404.","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12 Demeter J, Poros A, B\u00f6d\u00f6r Cs, et al. Chronic myelogenous leukemia: diagnosis and treatment. [A kr\u00f3nikus myeloid leukaemia korszer\u0171 diagnosztik\u00e1ja \u00e9s kezel\u00e9se.] Orv Hetil. 2016; 157: 1459-1468. [Hungarian]","DOI":"10.1556\/650.2016.30521"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"13 Steegmann","year":"2016","unstructured":"13 Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30: 1648-1671.","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2019.10.036","article-title":"Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors","volume":"301","author":"14 Caocci","year":"2020","unstructured":"14 Caocci G, Mulas O, Annunziata M, et al. Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. Int J Cardiol. 2020; 301: 163-166.","journal-title":"Int J Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","article-title":"Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"16","author":"15 Haguet","year":"2017","unstructured":"15 Haguet H, Douxfils J, Mullier F, et al. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017; 16: 5-12.","journal-title":"Expert Opin Drug Saf"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"16 Dahl\u00e9n","year":"2016","unstructured":"16 Dahl\u00e9n T, Edgren G, Lambe M, et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med. 2016; 165: 161-166.","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"17 Valent","year":"2015","unstructured":"17 Valent P, Hadzijusufovic E, Schernthaner GH, et al. Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood 2015; 125: 901-906.","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0741-5214(97)70045-4","article-title":"Recommended standards for reports dealing with lower extremity ischemia: revised version","volume":"26","author":"18 Rutherford","year":"1997","unstructured":"18 Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997; 26: 517-538.","journal-title":"J Vasc Surg"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)","volume":"37","author":"19 Piepoli","year":"2016","unstructured":"19 Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J. 2016; 37: 2315-2381.","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"20 Quint\u00e1s-Cardama","year":"2007","unstructured":"20 Quint\u00e1s-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007; 25: 3908-3914.","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management","volume":"17","author":"21 Cortes","year":"2017","unstructured":"21 Cortes JE, Jimenez CA, Mauro MJ, et al. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk. 2017; 17: 78-82.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"22 Hughes","year":"2019","unstructured":"22 Hughes TP, Laneuville P, Rousselot P, et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica 2019; 104: 93-101.","journal-title":"Haematologica"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial","volume":"27","author":"23 Apperley","year":"2009","unstructured":"23 Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol. 2009; 27: 3472-3479.","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"24 Montani","year":"2012","unstructured":"24 Montani D, Bergot E, G\u00fcnther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO.2002.99.179","article-title":"Hypersensitivity pneumonitis related to imatinib mesylate","volume":"20","author":"25 Bergeron","year":"2002","unstructured":"25 Bergeron A, Bergot E, Vilela G, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol. 2002; 20: 4271-4272.","journal-title":"J Clin Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.leukres.2007.01.024","article-title":"Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib","volume":"31","author":"26 Breccia","year":"2007","unstructured":"26 Breccia M, Muscaritoli M, Gentilini F, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res. 2007; 31: 1770-1772.","journal-title":"Leuk Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00432-017-2402-x","article-title":"Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis","volume":"143","author":"27 Giles","year":"2017","unstructured":"27 Giles FJ, Rea D, Rosti G, et al. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol. 2017; 143: 1585-1596.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.leukres.2008.01.015","article-title":"Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib","volume":"32","author":"28 Breccia","year":"2008","unstructured":"28 Breccia M, Muscaritoli M, Cannella L, et al. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res. 2008; 32: 1626-1628.","journal-title":"Leuk Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1056\/NEJMc052500","article-title":"Imatinib and hyperlipidemia","volume":"353","author":"29 Gottardi","year":"2005","unstructured":"29 Gottardi M, Manzato E, Gherlinzoni F. Imatinib and hyperlipidemia. N Engl J Med. 2005; 353: 2722-2723.","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"30 Aichberger","year":"2011","unstructured":"30 Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011; 86: 533-539.","journal-title":"Am J Hematol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"31 Cortes","year":"2018","unstructured":"31 Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018; 36: 231-237.","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis","volume":"39","author":"32 Teo","year":"2013","unstructured":"32 Teo YL, Ho HK, Chan A. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev. 2013; 39: 199-206.","journal-title":"Cancer Treat Rev"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"6608","DOI":"10.3748\/wjg.v13.i48.6608","article-title":"Imatinib-induced fatal acute liver failure","volume":"13","author":"33 Ridruejo","year":"2007","unstructured":"33 Ridruejo E, Cacchione R, Villamil AG, et al. Imatinib-induced fatal acute liver failure. World J Gastroenterol. 2007; 13: 6608-6611.","journal-title":"World J Gastroenterol"},{"key":"ref33","unstructured":"34 Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006; 91(6 Suppl): ECR27."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/cncr.24257","article-title":"Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy","volume":"115","author":"35 Quint\u00e1s-Cardama","year":"2009","unstructured":"35 Quint\u00e1s-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009; 115: 2482-2490.","journal-title":"Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1080\/09537104.2018.1501470","article-title":"Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia","volume":"30","author":"36 Mezei","year":"2019","unstructured":"36 Mezei G, Debreceni IB, Kerenyi A, et al. Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia. Platelets 2019; 30: 836-843.","journal-title":"Platelets"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3324\/haematol.2009.010496","article-title":"Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure","volume":"94","author":"37 Palandri","year":"2009","unstructured":"37 Palandri F, Castagnetti F, Soverini S, et al. Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. Haematologica 2009; 94: 1758-1761.","journal-title":"Haematologica"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.leukres.2016.07.008","article-title":"CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment","volume":"48","author":"38 Nicolini","year":"2016","unstructured":"38 Nicolini FE, Alcazer V, Huguet F, et al. CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment. Leuk Res. 2016; 48: 80-83.","journal-title":"Leuk Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.6004\/jnccn.2009.0069","article-title":"Issues of imatinib and pregnancy outcome","volume":"7","author":"39 Apperley","year":"2009","unstructured":"39 Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw. 2009; 7: 1050-1058.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40 Carlier P, Markarian M, Bernard N, et al. Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers. Arch Gynecol Obstet. 2017; 295: 269-271. [Erratum: Arch Gynecol Obstet. 2017; 295: 1059.]","DOI":"10.1007\/s00404-016-4262-z"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/ejh.13215","article-title":"Risks and challenges of CML management during pregnancy: looking for a balanced decision","volume":"102","author":"Chelysheva E","year":"2019","unstructured":"41 Chelysheva E, Turkina A. Risks and challenges of CML management during pregnancy: looking for a balanced decision. Eur J Haematol. 2019; 102: 378-379.","journal-title":"Eur J Haematol"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/30\/article-p1198.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/30\/article-p1198.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T15:01:29Z","timestamp":1698678089000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/30\/article-p1198.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,25]]},"references-count":41,"journal-issue":{"issue":"30"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32177","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,25]]}}}